Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 382 clinical trials
featured
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

. Researchers want to see if this therapy fights kidney cancer cells. Metastatic renal cell carcinoma (RCC) is an incurable condition. Current therapy for this disease consists of the serial administration

carcinoma
clear cell carcinoma
clear cell renal cell carcinoma
metastatic cancer
renal cell cancer
  • 144 views
  • 22 Dec, 2020
  • 1 location
featured
PHASE III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL EVALUATING THE USE OF ADJUVANT ENDOCRINE THERAPY +/- ONE YEAR OF EVEROLIMUS IN PATIENTS WITH HIGH-RISK, HORMONE RECEPTOR-POSITIVE AND HER2/NEU NEGATIVE BREAST CANCER.

PHASE III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL EVALUATING THE USE OF ADJUVANT ENDOCRINE THERAPY +/- ONE YEAR OF EVEROLIMUS IN PATIENTS WITH HIGH-RISK, HORMONE RECEPTOR-POSITIVE AND HER2/NEU NEGATIVE BREAST CANCER.

HER2
breast cancer
erbb2
endocrine therapy
hormone therapy
  • 220 views
  • 24 Nov, 2020
  • 1 location
featured
AREN03B2: Study of Kidney Tumors in Young Patients

AREN03B2: Study of Kidney Tumors in Young Patients

  • 36 views
  • 08 Nov, 2020
  • 1 location
featured
AREN03B2: Renal Tumors Classification, Biology, and Banking Study

AREN03B2: Renal Tumors Classification, Biology, and Banking Study

  • 106 views
  • 08 Nov, 2020
  • 1 location
featured
A Phase 1b, Dose-escalation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With REGN2810 (Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)

This is a Phase 1b, open-label, multi-center, dose-escalation trial of Pexa-Vec plus REGN2810 in patients with metastatic or unresectable renal cell carcinoma (RCC). The trial consists of a dose-escalation stage, where the maximum feasible dose of Pexa-Vec in combination with REGN2810 will be determined, followed by an expansion stage. During …

renal function tests
renal cell cancer
carcinoma
programmed cell death 1 ligand 1
karnofsky performance status
  • 0 views
  • 23 Nov, 2020
  • 3 locations
featured
A Phase 1/1b Study of Sitravatinib in Combination with Nivolumab and Ipilimumab in Patients with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

Study 516-008 is an open-label Phase 1 dose escalation/Phase 1b dose expansion study evaluating the safety and tolerability, clinical activity, and PK of sitravatinib in combination with nivolumab and ipilimumab for the treatment of ccRCC and potentially other solid tumor types. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor …

carcinoma
tyrosine
ipilimumab
VEGFR2
monoclonal antibodies
  • 27 views
  • 15 Sep, 2020
  • 1 location
featured
Procurement of Human Biospecimens for Research

Procurement of Human Biospecimens for Research

  • 80 views
  • 23 Nov, 2020
  • 1 location
featured
Procurement of Human Biospecimens for Research

Procurement of Human Biospecimens for Research

  • 53 views
  • 23 Nov, 2020
  • 1 location
Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy before surgery may shrink the tumor so it can be removed during surgery. Giving more chemotherapy after surgery may kill any remaining tumor cells. It is not …

nephroblastoma
tumor cells
conventional surgery
cyclophosphamide
  • 9 views
  • 07 Nov, 2020
  • 1 location
MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

To compare the efficacy of Medroxyprogesterone Acetate with dydrogesterone in patients having endometrial hyperplasia (EH) without atypia.

  • 0 views
  • 29 Aug, 2021
  • 1 location